The possible interconnection between the eye and central nervous system (CNS) has been
a topic of discussion for several years just based on fact that the eye is properly considered …

A number of pharmacological targets are exploited to modify the parameters in the
Goldmann equation and reduce the intraocular pressure (IOP). This strategy constitutes the …

Contact lenses (CLs) offer a wide variety of advantages as ocular drug-releasing platforms,
but the feasibility of medicated CL development is constrained by numerous scientific …

Glaucoma is extensively treated with topical eye drops containing drugs. However, the
retention time of the loaded drugs and the in vivo bioavailability of the drugs are highly …

Glaucoma is a complex group of optic neuropathies that affects both humans and animals.
Intraocular pressure (IOP) elevation is a major risk factor that results in the loss of retinal …

Glaucoma is a chronic and progressive neurodegenerative disease characterized by the
loss of retinal ganglion cells and visual field defects, currently affecting around 1% of the …

An intracameral (IC) injection directly delivers the drug into the anterior chamber of the eye.
This targeted drug delivery technique overcomes the ocular barriers and offers a high …

Due to the very low bioavailability of drugs administered to the surface of the eyeball, issues
related to the formulation of an ophthalmic drug pose a technological challenge. The …

Objectives To develop a sustained release 5-fluorouracil (5-FU) implant by three-
dimensional (3D) printing to effectively prevent conjunctival fibrosis after glaucoma surgery …

Glaucoma is one of the world's leading causes of blindness, and its management is
challenging. The main objective is to lower intraocular pressure through medical, para …